Intervention Review

You have free access to this content

Complement inhibitors for age-related macular degeneration

  1. Michael A Williams1,*,
  2. Gareth J McKay2,
  3. Usha Chakravarthy3

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 15 JAN 2014

Assessed as up-to-date: 21 NOV 2013

DOI: 10.1002/14651858.CD009300.pub2


How to Cite

Williams MA, McKay GJ, Chakravarthy U. Complement inhibitors for age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD009300. DOI: 10.1002/14651858.CD009300.pub2.

Author Information

  1. 1

    Royal Victoria Hospital, Medical Ophthalmology, Eye and Ear Clinic, Belfast, Northern Ireland, UK

  2. 2

    Queen's University Belfast, Centre for Public Health, Belfast, Northern Ireland, UK

  3. 3

    Queen's University Belfast, Centre for Vision and Vascular Science, Belfast, Northern Ireland, UK

*Michael A Williams, Medical Ophthalmology, Eye and Ear Clinic, Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland, BT12 6BA, UK. m.williams@qub.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 15 JAN 2014

SEARCH

 
Characteristics of ongoing studies [ordered by study ID]
NCT00935883

Trial name or title'Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration' (COMPLETE)

MethodsRandomised, double-arm, double-masked, phase II trial

ParticipantsOver 50 years with nonexudative AMD and no history of CNV in the study eye, BCVA of 20/63 (or 59 letters) or better and no confounding ocular conditions

InterventionsIntravenous eculizumab or intravenous saline

OutcomesPrimary outcome: growth in GA/change in drusen volume

Starting dateJuly 2009

Contact informationPrincipal investigator: Philip J Rosenfeld, MD, PhD

NotesNCT00935883 is active but not recruiting, having had a final data collection date of June 2012

NCT00950638

Trial name or title'A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry AMD'

MethodsRandomised, open-label, dose comparison, parallel assignment, phase I study

ParticipantsOver 50 years of age with dry AMD in both eyes

InterventionsARC1905 intravitreal injection (dose comparison)

OutcomesPresence of any dose-limiting toxicity; safety endpoints include adverse events, vital signs, ophthalmic variables and outcomes

Starting dateJuly 2009

Contact informationOphthotech Corporation, New York, USA

NotesNCT00950638 is examining the safety and tolerability of intravitreal ARC-1905 for GA secondary to AMD. It is active but not recruiting, with a final data collection date of September 2012